Real ‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population

ConclusionsRW HOCM patients differ from the EXPLORER-HCM population for their older age, lower LVEF and larger atrial volume, potentially reflecting a more advanced stage of the disease. About half of RW HOCM patients were found eligible to mavacamten.This article is protected by copyright. All rights reserved.

Source: European Journal of Heart Failure - December 23, 2023 Category: Cardiology Authors: Edoardo Bertero, Chiara Chiti, Maria Alessandra Schiavo, Giacomo Tini, Paolo Costa, Giancarlo Todiere, Barbara Mabritto, Lorenzo ‐Lupo Dei, Alessia Giannattasio, Davide Mariani, Carla Lofiego, Caterina Santolamazza, Emanuele Monda, Giovanni Tags: Short Report Source Type: research